Development of SDP0505: a first-in-class HER3 × c-Met bispecific ADC, demonstrates potent antitumor activity in EGFR TKI-resistant NSCLC, CRC, and beyond.

Antib Ther · 2026 · PMC13175982 · PMID 42145655

Europe PMC DOI

hedged sentence

0.0010

closest p · 0.0× alpha

0.0010

boldest claim

The sentences

highly significantP < .001actually significant

At Day 35, SDP0505 demonstrated dose-dependent tumor growth inhibition, with 3 and 10 mg/kg doses showing highly significant efficacy versus vehicle control ( P < .001; TGI: 91% and 95%, respectively).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.